Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
Author:
Affiliation:
1. Agency for Care Effectiveness (ACE), Ministry of Health Singapore
2. National University Cancer Institute (NCIS) Singapore
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1308
Reference33 articles.
1. National Registry of Diseases Office.Singapore Cancer Registry 50th Anniversary Monograph (1968–2017).2019.
2. Incidence and mortality of female breast cancer in the Asia‐Pacific region;Youlden DR;Cancer Biol Med,2014
3. Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers
4. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
5. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA;PharmacoEconomics;2023-03-15
2. Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence;Saudi Pharmaceutical Journal;2022-08
3. Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis;BMJ Open;2022-05
4. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) breast cancer: a systematic review;Annals of Translational Medicine;2022-02
5. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors;Journal of Medical Economics;2021-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3